Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568996 | 1.00 | DDB1 (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26372301 | 1.00 | DDB1 (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26372292 | 0.96 | DDB1 (0.66) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26317539 | 0.94 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24922300 | 0.91 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL28503445 | 0.90 | DDB1 (0.62) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22636788 | 0.89 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21070618 | 0.89 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22443118 | 0.89 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL31411864 | 0.89 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2021057872-A1 | PROTAC SMALL MOLECULE COMPOUND AND APPLICATION THEREOF | 珠海宇繁生物科技有限责任公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | DDB1 395/4885CRBN 65/4885IKZF3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.